Filtered By:
Condition: Diabetes Type 2
Cancer: Carcinoma

This page shows you your search results in order of date.

Order by Relevance | Date

Total 22 results found since Jan 2013.

Differentially Expressed Genes Analysis in the Human Small Airway Epithelium of Healthy Smokers Shows Potential Risks of Disease Caused by Oxidative Stress and Inflammation and the Potentiality of Astaxanthin as an Anti-Inflammatory Agent
This study aims to observe differentially expressed genes (DEGs) in the human small airway epithelium of smokers compared to genes whose expression changes due to astaxanthin (AST) treatment, an antioxidant compound that can modulate Nrf2. Gene expression data that was stored in the GEO browser (GSE 11952) was analyzed using GEO2R to search for DEG among smokers and nonsmokers subject. DEG was further compared to those genes whose expression changes due to astaxanthin treatment (AST) that were obtained from the Comparative Toxicogenomics Database (CTD; https://ctdbase.org/). DEG (p < 0.05) analysis result shows that the...
Source: International Journal of Inflammation - March 13, 2023 Category: Allergy & Immunology Authors: Irandi Putra Pratomo Aryo Tedjo Dimas R Noor None Rosmalena Source Type: research

A review on the role of ADAMTS9-AS2 in different disorders
Pathol Res Pract. 2023 Jan 27;243:154346. doi: 10.1016/j.prp.2023.154346. Online ahead of print.ABSTRACTRecent decade has seen a tremendous progress in identification of the role of different long non-coding RNAs (lncRNAs) in human pathologies. ADAMTS9-AS2 is an example of lncRNAs with different roles in human disorders. It is mostly acknowledged as a tumor suppressor lncRNA in different types of cancers. However, it has been reported to be up-regulated in tongue squamous cell carcinoma, salivary adenoid cystic carcinoma and glioblastoma. Moreover, ADAMTS9-AS2 is possibly involved in the pathoetiology of pulpitis, acute is...
Source: Pathology, Research and Practice - February 6, 2023 Category: Pathology Authors: Soudeh Ghafouri-Fard Arian Askari Bashdar Mahmud Hussen Aria Baniahmad Mohammad Taheri Majid Mokhtari Source Type: research

New insights into the comorbid conditions of Turner syndrome: results from a long-term monocentric cohort study
ConclusionsThis cohort study confirms the need for continuous, structured and multidisciplinary lifelong monitoring of TS, thus ensuring the early diagnosis of important comorbid conditions, including cancer, and their appropriate and timely treatment. In addition, these data highlight the need for the increased surveillance of specific types of cancer in TS, including thyroid carcinoma.
Source: Journal of Endocrinological Investigation - November 11, 2022 Category: Endocrinology Source Type: research

Sphingosine 1-phosphate and its regulatory role in vascular endothelial cells
We presently review the levels of S1P in those vascular and vascular-related diseases. Plasma S1P levels were reduced in various inflammation-related diseases such as atherosclerosis and sepsis, but were increased in other diseases including type 2 diabetes, neurodegeneration, cerebrovascular damages such as acute ischemic stroke, Alzheimer's disease, vascular dementia, angina, heart failure, idiopathic pulmonary fibrosis, community-acquired pneumonia, and hepatocellular carcinoma. Then, we highlighted the molecular mechanism by which S1P regulated EC biology including vascular development and angiogenesis, inflammation, p...
Source: Atherosclerosis - February 4, 2022 Category: Cardiology Authors: Yan Qiu Junyi Shen Wenli Jiang Yi Yang Xiaoheng Liu Ye Zeng Source Type: research

Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis
Conclusion: Semaglutide should be considered when GLP-1 RAs are indicated for T2DM patients.
Source: Frontiers in Pharmacology - December 24, 2021 Category: Drugs & Pharmacology Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news